CompletedNCT00450775Updated Sep 25, 2008

Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

A Phase 4 interventional study of Dermatix Q in Scars, sponsored by Innovative Medical. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-09-25.

Sponsored by Innovative Medical · Phase 4, Interventional, and Prevention

Phase: Phase 4
Study type: Interventional
Enrollment: 12
Allocation: Randomized
Ages: 18 Years and older
Sex: All

Study summary

The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.

Conditions studied

Scars

In context

Lead sponsor

Innovative Medical is the lead sponsor of 50 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Female or male patients at least 18 years of age
Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc)
Able and willing to provide informed consent and likely to complete all study visits
All Fitzpatrick skin types will be evaluated

Exclusion criteria

Exclusion Criteria:

Known contraindications to Dermatix or any of its components
Age of scar is > 4 months
Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)

Study design

Phase: Phase 4
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Single group
Masking: None (open label)
Enrollment: 12 participants (estimated)

Study arms

Other
1
Drug: Dermatix Q

Interventions

DrugDermatix Q
Dermatix Q applied twice daily

What researchers measure

Primary outcomes

efficacy
Time frame: 1 yr

Secondary outcomes

patient acceptance
Time frame: 1 yr

Study locations

1 site

Dadeland Dermatology
Coral Gables, Florida 33134, United States

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Sep 25, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00450775
Lead sponsor: Innovative Medical
First posted: Mar 22, 2007
Start date: Mar 2007
Primary completion: Mar 2008
Completion: Mar 2008
Last update: Sep 25, 2008

Study contacts

David Rodriguez, MD

principal investigator · Dadeland Dermatology

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Innovative Medical

Start the discussion